Kalbe Farma's Q3 2025 Financial Performance Highlights

Strong Revenue and Profit Growth

PT Kalbe Farma (KLBF), a leading Indonesian pharmaceutical company, has reported robust financial results for the first nine months of 2025. The company achieved revenue of Rp25.99 trillion for Jan-Sep 2025, representing a 7.2% year-on-year increase. Net profit for the same period reached Rp2.63 trillion, marking a 10.6% growth compared to the previous year.

Q3 Performance Analysis

In the third quarter of 2025, KLBF continued its positive momentum with revenue reaching Rp8.01 trillion and net profit of Rp606 billion. This performance was supported by several key factors, including controlled growth in cost of goods sold (COGS) and significant increases in other operational income.

Margin Expansion

The company's profitability metrics showed notable improvement. Gross Profit Margin (GPM) expanded to 41% from 39% in Q3 2024, while Operating Profit Margin (OPM) improved to 13% from 12%. Net Profit Margin (NPM) also demonstrated substantial growth, rising to 10% from 7% in the same period last year.

Analyst Insights

Abdul Azis, Equity Research Analyst at Kiwoom Sekuritas, noted that KLBF's performance remained in line with expectations. The analyst highlighted that the upcoming rainy season is likely to provide additional support for revenue growth in Q4 2025. The controlled COGS growth of 4.82% and significant increase in other operational income (up 169.56%) were key drivers of the margin expansion.

Outlook

With improving profitability metrics and positive market conditions, KLBF is well-positioned for continued growth. The company's strong performance in the first nine months of 2025, coupled with favorable seasonal factors in Q4, suggests a promising outlook for the full year.